Liver Failure, Acute: Clinical Trials

12 trials for Liver Failure, Acute, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 not yet recruiting, 2 withdrawn, 1 terminated. 12 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 312Completed 5, Not yet recruiting 3, Withdrawn 2, Terminated 1, Unknown 1
Phase 24Not yet recruiting 2, Completed 1, Withdrawn 1

Follow Liver Failure, Acute: new trials by email Literature Review of Liver Failure, Acute trials Research Report on Liver Failure, Acute

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial
Umbilical cord Mesenchymal stem cell, Steroid, Standard Medical Treatment - Acute-On-Chronic Liver Failure
Phase 3Not yet recruitingInstitute of Liver and Biliary Sciences, India1002028-01-012025-08-17
Umbilical Cord-derived Mesenchymal Stem Cell Infusion for Treating ACLF
Low-dose experimental group, High-dose experimental group, Low-dose placebo control group - Acute-On-Chronic Liver Failure
Phase 2 / Phase 3Not yet recruitingNational Engineering Center of Cell Products962025-04-152025-03-19
Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed
Terlipressin Injectable Product - Acute on Chronic Liver Failure
Phase 2 / Phase 3Not yet recruitingInstitute of Liver and Biliary Sciences, India602025-02-102025-02-07
Plasma Exchange in Acute on Chronic Liver Failure
Plasma exchange, Standard medical treatment - Cirrhosis, Liver, Acute-On-Chronic Liver Failure
Phase 3UnknownAsian Institute of Gastroenterology, India1302019-08-152019-08-09
Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%
SMT + PE-A 5%, Standard Medical Treatment - Acute-On-Chronic Liver Failure
Phase 3TerminatedInstituto Grifols, S.A.2742019-06-172026-06-04
13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF
13C-Methacetin - Acute Liver Failure
Phase 2 / Phase 3CompletedUniversity of Texas Southwestern Medical Center762016-06-102020-12-22
Cardiox Liver Function Test Pivotal Trial
0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose - Hepatic Failure, Liver Failure
Phase 3WithdrawnCardiox Corporation2015-11-012016-01-15
Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure
Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO), Placebo - Acute on Chronic Hepatic Failure
Phase 3CompletedInstitute of Liver and Biliary Sciences, India552011-07-012016-12-06
Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion
ELAD (Extracorporeal Liver Assist System) - Acute Liver Failure
Phase 2 / Phase 3WithdrawnVital Therapies, Inc.2010-06-012013-12-04
The MARS® Albumin Dialysis System in Patients With Fulminant and Subfulminant Hepatic Failure
Molecular Adsorbent Recirculating System (MARS®) - Hepatitis
Phase 3CompletedAssistance Publique - Hôpitaux de Paris1102004-08-012011-02-17
N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure
N-acetylcysteine, Placebo - Acute Liver Failure, Hepatic Encephalopathy
Phase 3CompletedUniversity of Pittsburgh1842000-01-012016-07-28
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
N-acetylcysteine (NAC), Placebo - Acute Liver Failure
Phase 3CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1731998-06-012017-10-13

Narrower conditions

Acute-On-Chronic Liver Failure (6)  ·  Fibrosis (2)  ·  Hepatic Encephalopathy (2)  ·  Liver Failure (2)  ·  Gastrointestinal Diseases (1)  ·  Hepatitis (1)  ·  Hepatitis C (1)  ·  Hepatitis, Alcoholic (1)  ·  Liver Cirrhosis (1)  ·  Liver Diseases (1)  ·  Massive Hepatic Necrosis (1)  ·  Rare Diseases (1)

Broader conditions

Digestive System Diseases (12)  ·  Hepatic Insufficiency (12)  ·  Liver Diseases (11)  ·  Liver Failure (10)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Brain Diseases (2)  ·  Brain Diseases, Metabolic (2)  ·  Central Nervous System Diseases (2)  ·  Hepatitis (2)  ·  Metabolic Diseases (2)  ·  Nervous System Diseases (2)  ·  Nutritional and Metabolic Diseases (2)  ·  Alcohol-Induced Disorders (1)

Interventions

Acetylcysteine (2)  ·  Glucose (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Plasma Exchange (1)  ·  Steroids (1)  ·  Water (1)

Sponsors

Institute of Liver and Biliary Sciences, India (3)  ·  Asian Institute of Gastroenterology, India (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Cardiox Corporation (1)  ·  Instituto Grifols, S.A. (1)  ·  National Engineering Center of Cell Products (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  University of Pittsburgh (1)  ·  University of Texas Southwestern Medical Center (1)  ·  Vital Therapies, Inc. (1)

Countries

United States (5)  ·  India (3)  ·  France (2)  ·  United Kingdom (2)  ·  Austria (1)  ·  Belgium (1)  ·  Canada (1)  ·  Germany (1)  ·  Italy (1)  ·  Portugal (1)  ·  Spain (1)

Top investigators

Dr. Shiv Kumar Sarin, DM (1)  ·  Michael Jopling, MD (1)  ·  Robert A Ashley (1)  ·  Robert H Squires, M.D. (1)  ·  Robert J. Fontana, MD (1)  ·  Shiv Kumar Sarin, MD, DM (1)  ·  William M. Lee, MD (1)

Results publications

PMID 37183883, PMID 19524577, PMID 24126646, PMID 31421008

NIH funding

U01DK058369 (2), R01DK058369 (1), R03DK052827 (1), U01DK072146 (1)